Regencell Bioscience (RGC) Short Interest Ratio & Short Volume

Short interest is the volume of Regencell Bioscience shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 1,230,000 shares of RGC short. 4.03% of Regencell Bioscience's shares are currently sold short. Learn More on Regencell Bioscience's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.03% of Regencell Bioscience's floating shares are currently sold short.

Regencell Bioscience saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,230,000 shares, an increase of 17.1% from the previous total of 1,050,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Regencell Bioscience currently has issued a total of 0 shares. Some of Regencell Bioscience's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Regencell Bioscience currently has a public float of 30,490,000 shares.

4.03% of Regencell Bioscience's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Regencell Bioscience: argenex SE (3.31%), BioNTech SE Sponsored ADR (2.65%), Teva Pharmaceutical Industries Ltd. (3.49%), Insmed, Inc. (5.33%), Summit Therapeutics PLC (24.12%), Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S Sponsored ADR (0.28%), Moderna, Inc. (19.15%), Dr. Reddy's Laboratories Ltd (1.34%), Viatris Inc. (3.51%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling RGC is an investing strategy that aims to generate trading profit from Regencell Bioscience as its price is falling. RGC shares are trading down $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Regencell Bioscience occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RGC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RGC, twice per month. The most recent reporting period available is June, 30 2025.